UChicago Faculty Physician
Olwen Hahn, MD
Olwen Hahn, MD
UChicago Faculty Physician
Associate Professor of Medicine
Associate Section Chief of Outpatient Operations, Section of Hematology and Oncology
Medical Director, Hematology and Oncology Outpatient Clinics and Infusion Therapy
Specialties
- Hematology and Oncology (Cancer)
Locations
- Chicago - Hyde Park
- About
- Specialties & Areas of Expertise
- Locations & Patient Information
- Education & Research
- Accepted Insurance
- External Professional Relationships
Olwen Hahn, MD, specializes in the diagnosis and treatment of breast cancer. Dr. Hahn’s practice primarily focuses on treating patients with all forms of breast cancer. For a comprehensive range of breast cancer treatments, Dr. Hahn offers both standard of care, such as chemotherapy, targeted therapy and endocrine therapy, as well as therapeutic clinical trials in order to deliver the best care for her patients. She is also a proponent of using systemic therapy (chemotherapy, targeted therapy, immunotherapy or endocrine therapy) prior to surgery (neoadjuvant therapy) to better understand how each patient’s individual tumor responds to therapy.
In addition to her clinical practice, Dr. Hahn is committed to elevating cancer care through clinical trials, and is a strong advocate in offering clinical trials to her patients. Additionally, she has worked with the National Cancer Institute (NCI)-sponsored cooperative group Cancer and Leukemia Group B (CALGB) and the Alliance for Clinical Trials in Oncology as an Executive Officer between 2008-2017, where she assisted in the development and conduct of oncology clinical trials. In 2019, she assumed the position of Director and Principal Investigator of the Alliance Central Protocol Operations Program. In this role, Dr. Hahn oversees the clinical operations for a large portfolio of multi-institutional, national oncology studies.
In addition to her clinical practice, Dr. Hahn is committed to elevating cancer care through clinical trials, and is a strong advocate in offering clinical trials to her patients. Additionally, she has worked with the National Cancer Institute (NCI)-sponsored cooperative group Cancer and Leukemia Group B (CALGB) and the Alliance for Clinical Trials in Oncology as an Executive Officer between 2008-2017, where she assisted in the development and conduct of oncology clinical trials. In 2019, she assumed the position of Director and Principal Investigator of the Alliance Central Protocol Operations Program. In this role, Dr. Hahn oversees the clinical operations for a large portfolio of multi-institutional, national oncology studies.
Specialties
Areas of Expertise
UChicago Medicine Duchossois Center for Advanced Medicine - Hyde Park5758 S. Maryland Ave., Chicago IL 606371-888-824-0200
Board Certifications
- Internal Medicine
- Medical Oncology
Practicing Since
- 2007
Languages Spoken
- English
Medical Education
- Emory University School of Medicine
Residency
- University of Chicago Medicine
Fellowship
- University of Chicago Medicine
Memberships & Medical Societies
- American Society of Clinical Oncology
News & Research
Insurance
- Aetna Better Health *see insurance page
- Aetna HMO (specialists only)
- Aetna Medicare Advantage HMO & PPO
- Aetna POS
- Aetna PPO
- BCBS Blue Precision HMO (specialists only)
- BCBS HMO (HMOI) (specialists only)
- BCBS Medicare Advantage HMO & PPO
- BCBS PPO
- Cigna HMO
- Cigna POS
- Cigna PPO
- CountyCare *see insurance page
- Humana Medicare Advantage Choice PPO
- Humana Medicare Advantage Gold Choice PFFS
- Humana Medicare Advantage Gold Plus HMO
- Medicare
- Multiplan PPO
- PHCS PPO
- United Choice Plus POS/PPO
- United Choice HMO (specialists only)
- United Options (PPO)
- United Select (HMO & EPO) (specialists only)
- United W500 Emergent Wrap
- University of Chicago Health Plan (UCHP)
Our list of accepted insurance providers is subject to change at any time. You should contact your insurance company to confirm UChicago Medicine participates in their network before scheduling your appointment. If you have questions regarding your insurance benefits at UChicago Medicine, please contact our financial counseling team at OPSFinancialCounseling@uchospitals.edu.
UChicago Medicine is committed to fostering a corporate culture of ethical behavior and integrity in all matters related to compliance with the laws and regulations that govern the delivery of healthcare. This aspiration is central to supporting patient care, research, and teaching at UChicago Medicine.
Some of our physicians and health professionals collaborate with external pharmaceutical, medical device, or other medical related entities to develop new treatments and products to improve clinical outcomes for patients. In some instances, the physician has ownership interests in the external entity and/or is compensated for advising or speaking about the entity’s products or treatments. These payments may include compensation for consulting and speaking engagements, equity, and/or royalties for products invented by our physicians. To assure objectivity and integrity in patient care, UChicago Medicine requires all physicians and health professionals to report their relationships and financial interests with external entities on an annual basis. This information is used to review relationships and transactions that might give rise to potential financial conflicts of interest, and when considered to be significant a management plan to mitigate any biases is created.
If you are a patient at UChicago Medicine and would like more information about your physician’s external relationships, please talk with your physician. You may also visit the Centers for Medicare & Medicaid Services (CMS) Open Payments website at https://openpaymentsdata.cms.gov/ . CMS Open Payments is a national disclosure program that promotes a more transparent and accountable health care system. It houses a publicly accessible database of payments that reporting entities, including drug and medical device companies, make to covered recipients like physicians and hospitals.
Information in the CMS Open Payments database could potentially contain inaccurately reported and out of date payment information. All information is open to personal interpretation, if there are questions about the data, patients and their advocates should speak directly to their health care provider for a better understanding.
Some of our physicians and health professionals collaborate with external pharmaceutical, medical device, or other medical related entities to develop new treatments and products to improve clinical outcomes for patients. In some instances, the physician has ownership interests in the external entity and/or is compensated for advising or speaking about the entity’s products or treatments. These payments may include compensation for consulting and speaking engagements, equity, and/or royalties for products invented by our physicians. To assure objectivity and integrity in patient care, UChicago Medicine requires all physicians and health professionals to report their relationships and financial interests with external entities on an annual basis. This information is used to review relationships and transactions that might give rise to potential financial conflicts of interest, and when considered to be significant a management plan to mitigate any biases is created.
If you are a patient at UChicago Medicine and would like more information about your physician’s external relationships, please talk with your physician. You may also visit the Centers for Medicare & Medicaid Services (CMS) Open Payments website at https://openpaymentsdata.cms.gov/ . CMS Open Payments is a national disclosure program that promotes a more transparent and accountable health care system. It houses a publicly accessible database of payments that reporting entities, including drug and medical device companies, make to covered recipients like physicians and hospitals.
Information in the CMS Open Payments database could potentially contain inaccurately reported and out of date payment information. All information is open to personal interpretation, if there are questions about the data, patients and their advocates should speak directly to their health care provider for a better understanding.